MA50972A - Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide - Google Patents
Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamideInfo
- Publication number
- MA50972A MA50972A MA050972A MA50972A MA50972A MA 50972 A MA50972 A MA 50972A MA 050972 A MA050972 A MA 050972A MA 50972 A MA50972 A MA 50972A MA 50972 A MA50972 A MA 50972A
- Authority
- MA
- Morocco
- Prior art keywords
- pyrazol
- ylmethyl
- pyridin
- acetamide
- cyclopropyl
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017066806 | 2017-07-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA50972A true MA50972A (fr) | 2020-10-14 |
Family
ID=63079885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA050972A MA50972A (fr) | 2017-07-05 | 2018-07-04 | Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11059803B2 (https=) |
| EP (1) | EP3649117B1 (https=) |
| JP (2) | JP2020525475A (https=) |
| KR (1) | KR102645911B1 (https=) |
| CN (1) | CN110831932A (https=) |
| AU (1) | AU2018296423B2 (https=) |
| BR (1) | BR112020000099A2 (https=) |
| CA (1) | CA3067489A1 (https=) |
| CL (1) | CL2020000002A1 (https=) |
| EA (1) | EA202090193A1 (https=) |
| IL (1) | IL271764B2 (https=) |
| MA (1) | MA50972A (https=) |
| MY (1) | MY206357A (https=) |
| PH (1) | PH12020500040A1 (https=) |
| SG (1) | SG11201912881SA (https=) |
| UA (1) | UA126582C2 (https=) |
| WO (1) | WO2019008034A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110072521B (zh) | 2016-12-16 | 2022-11-29 | 爱杜西亚药品有限公司 | 包含t型钙通道阻断剂的药物组合 |
| MA47409A (fr) | 2017-02-06 | 2019-12-11 | Idorsia Pharmaceuticals Ltd | Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes |
| EP3649117B1 (en) * | 2017-07-05 | 2024-10-09 | Idorsia Pharmaceuticals Ltd | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
| TW202128158A (zh) | 2019-12-20 | 2021-08-01 | 瑞士商愛杜西亞製藥有限公司 | 包含n-[1-(5-氰基-吡啶-2-基甲基)-1h-吡唑-3-基]-2-[4-(1-三氟甲基-環丙基)-苯基]-乙醯胺之醫藥組合物 |
| EP4389892A4 (en) * | 2021-08-17 | 2025-12-10 | Korea Advanced Inst Sci & Tech | Antisense oligonucleotide targeting the CAV3.1 gene and its uses |
| WO2023240205A1 (en) | 2022-06-10 | 2023-12-14 | Neurocrine Biosciences, Inc. | Deuterated compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6195684B2 (ja) * | 2014-06-03 | 2017-09-13 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | ピラゾール化合物及びｔ型カルシウムチャンネルブロッカーとしてのそれらの使用 |
| WO2016041892A1 (en) | 2014-09-15 | 2016-03-24 | Actelion Pharmaceuticals Ltd | Triazole compounds as t-type calcium channel blockers |
| CN110072521B (zh) | 2016-12-16 | 2022-11-29 | 爱杜西亚药品有限公司 | 包含t型钙通道阻断剂的药物组合 |
| MA47409A (fr) | 2017-02-06 | 2019-12-11 | Idorsia Pharmaceuticals Ltd | Nouveau procédé de synthèse de 1-aryl-1-trifluorométhylcyclopropanes |
| EP3649117B1 (en) * | 2017-07-05 | 2024-10-09 | Idorsia Pharmaceuticals Ltd | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |
-
2018
- 2018-07-04 EP EP18749304.4A patent/EP3649117B1/en active Active
- 2018-07-04 MA MA050972A patent/MA50972A/fr unknown
- 2018-07-04 CN CN201880044771.7A patent/CN110831932A/zh active Pending
- 2018-07-04 IL IL271764A patent/IL271764B2/en unknown
- 2018-07-04 CA CA3067489A patent/CA3067489A1/en active Pending
- 2018-07-04 SG SG11201912881SA patent/SG11201912881SA/en unknown
- 2018-07-04 US US16/628,618 patent/US11059803B2/en active Active
- 2018-07-04 AU AU2018296423A patent/AU2018296423B2/en not_active Ceased
- 2018-07-04 BR BR112020000099-0A patent/BR112020000099A2/pt active Search and Examination
- 2018-07-04 EA EA202090193A patent/EA202090193A1/ru unknown
- 2018-07-04 UA UAA202000506A patent/UA126582C2/uk unknown
- 2018-07-04 MY MYPI2020000011A patent/MY206357A/en unknown
- 2018-07-04 JP JP2019572102A patent/JP2020525475A/ja active Pending
- 2018-07-04 WO PCT/EP2018/068087 patent/WO2019008034A1/en not_active Ceased
- 2018-07-04 KR KR1020207002894A patent/KR102645911B1/ko active Active
-
2020
- 2020-01-02 CL CL2020000002A patent/CL2020000002A1/es unknown
- 2020-01-03 PH PH12020500040A patent/PH12020500040A1/en unknown
-
2021
- 2021-06-11 US US17/345,844 patent/US11555025B2/en active Active
-
2023
- 2023-06-26 JP JP2023104050A patent/JP2023123679A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20210300894A1 (en) | 2021-09-30 |
| KR20200018698A (ko) | 2020-02-19 |
| EA202090193A1 (ru) | 2020-06-03 |
| CL2020000002A1 (es) | 2020-07-31 |
| IL271764A (en) | 2020-02-27 |
| EP3649117B1 (en) | 2024-10-09 |
| US11555025B2 (en) | 2023-01-17 |
| IL271764B1 (en) | 2023-06-01 |
| SG11201912881SA (en) | 2020-01-30 |
| JP2020525475A (ja) | 2020-08-27 |
| US11059803B2 (en) | 2021-07-13 |
| AU2018296423A1 (en) | 2020-02-20 |
| JP2023123679A (ja) | 2023-09-05 |
| BR112020000099A2 (pt) | 2020-07-07 |
| MY206357A (en) | 2024-12-12 |
| KR102645911B1 (ko) | 2024-03-08 |
| CA3067489A1 (en) | 2019-01-10 |
| US20200165221A1 (en) | 2020-05-28 |
| CN110831932A (zh) | 2020-02-21 |
| IL271764B2 (en) | 2023-10-01 |
| WO2019008034A1 (en) | 2019-01-10 |
| UA126582C2 (uk) | 2022-11-02 |
| EP3649117A1 (en) | 2020-05-13 |
| AU2018296423B2 (en) | 2022-07-28 |
| PH12020500040A1 (en) | 2020-10-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA50972A (fr) | Forme cristalline de n-[1-(5-cyano-pyridin-2-ylméthyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluorométhyl-cyclopropyl)-phényl]-acétamide | |
| IL274488B1 (en) | Crystal forms of n-(4-(4-(cyclopropylmethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide | |
| IL280782A (en) | Inhibiting αv β6 integrin | |
| EP3431075A4 (en) | EDARAVONDARREICHUNGSFORM | |
| IL271726A (en) | Compositions and methods of use of 2-(4-chlorophenyl)-N-((2-(2, 6-doxopyridin-3-yl)-1-oxoisoinodolin-5-yl)methyl)2-2-difluoroacetamide | |
| GB201609607D0 (en) | Polymorphs of N-(3-Fluoro-4-methoxypyridin-2-yl)methyl)-3-(methoxymethyl)-1-({4-((2-oxopy ridin-1-yl)methyl)phenyl}methyl)pyrazole-4-carboxamide and salts | |
| DK3578547T3 (da) | Sulfonylureaer og relaterede forbindelser og brug af samme | |
| HUE063043T2 (hu) | Eljárás N-(5-(4-(4-formil-3-fenil-1H-pirazol-1-il)-pirimidin-2-il-amino)-4-metoxi-2-morfolinofenil)-akrilamid elõállítására | |
| IL263004B (en) | A new crystalline form of n-[5-(5,3-difluoro-benzyl)-h1-indazol-3-yl]-4-(4-methyl-piperazin-1-yl)-2-(tetrahydro-pyran-4 -ilamino)-benzamide | |
| DK3154950T3 (da) | N-(cyanmethyl)-4-(2-(4-morpholinphenylamino)pyrimidin-4-yl)benzamidhydrochloridsalte | |
| HUE041725T2 (hu) | (S)-1-(2-hidroxietil)-4-metil-N-[4-(metilszulfonil)fenil]-5-[2-(trifluormetil)fenil]-1H-pirrol-3-karboxamid kristálya | |
| IL252900B (en) | Formulations of 2-(tert-butylamino)-4-((1r,3r,4r)-3-hydroxy-4-methycyclohexylamino)-pyrimidine-5-carboxamide | |
| EP3263553A4 (en) | Crystalline modification of n-(2-(3-phenylureido)phenyl)benzenesulfonamide and recording material using same | |
| SG10202007913WA (en) | Formulations of 2-(4-chlorophenyl)-n-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide | |
| EP3337485A4 (en) | CRYSTALLINE FORMS OF IBRUTINIB | |
| DK3255046T3 (da) | Hydroxyethylsulfonat af cyclin-afhængig proteinkinasehæmmer, krystallinsk form deraf og fremgangsmåde til fremstilling deraf | |
| HUE062726T2 (hu) | 1-(1,2-dimetilpropil)-N-etil-5-metil-N-piridazin-4-il-pirazol-4-karboxamid kristályos formái | |
| EP3313396A4 (en) | G-PROTEIN-COUPLED RECEPTOR CINASE INHIBITORS AND METHOD OF USE THEREOF | |
| SI3752129T1 (sl) | Večnamenski sestavek torasemida | |
| EP3853665A4 (en) | ESTIMATION OF ASYMMETRIC ABERRATIONS | |
| HK40025427A (en) | Crystalline form of n -[1-(5-cyano-pyridin-2-ylmethyl)-1 h -pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide | |
| EP3773536A4 (en) | 1,4-SUBSTITUTES OF ISOQUINOLINE USED AS PROTEIN-PROTEIN INTERACTION INHIBITORS BETWEEN KEAP1 / NRF2 | |
| PL3643704T3 (pl) | Nowe produkty pośrednie do wytwarzania chlorowodorku remifentanilu | |
| IT201700050223A1 (it) | Procedimento per la preparazione di dexlansoprazolo cristallino | |
| HK40076150A (en) | Pharmaceutical compositions comprising n-[1-(5-cyano-pyridin-2-ylmethyl)-1h-pyrazol-3-yl]-2-[4-(1-trifluoromethyl-cyclopropyl)-phenyl]-acetamide |